Moderna and Merck report encouraging skin cancer vaccine data
Merck and Moderna announced positive results from the final phase of trials for their experimental skin cancer vaccine, particularly for advanced melanoma, using mRNA technology. The studies showed a statistically significant improvement in the relapse-free survival rate when the treatment was used alongside the drug Keytruda, compared to Keytruda alone, although specific numbers were not disclosed. This personalized therapy is based on the genetic mutations present in each patient's tumor, aiming to activate the immune system to attack the cancer cells. These results are considered a significant milestone, as they represent the first positive outcomes from the third phase of clinical trials of mRNA-based cancer treatments. The data are expected to be submitted for regulatory approval at an upcoming medical conference.
Notice: This Is an AI-Generated Summary
Comments (0)